Sign in to view content

48-Week End of Study Results From BEHOLD Phase 2 Study of UBX1325 in Patients With DME

Arshad M. Khanani, MD, MA, FASRS

Video
Published 2023

Related

Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy
Michael J Allingham, MD, PhD
Annual Meeting Talks
2022
Risk for Sight-Threatening Diabetic Retinopathy With GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes
Andrew J. Barkmeier, MD
Annual Meeting Talks
2024
Evaluation of Nonperfusion Area and Other Vascular Metrics by Widefield SS-OCTA as Biomarkers of Diabetic Retinopathy Severity
John B. Miller, MD
Annual Meeting Talks
2021

Category: Diabetic Retinopathy

See more